Literature DB >> 27862334

TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.

Nathan Ungerleider1, Chang Han1, Jinqiang Zhang1, Lu Yao1, Tong Wu1.   

Abstract

Transforming growth factor β (TGFβ) is a multifunctional cytokine which is importantly implicated in hepatocarcinogenesis. The current study provides novel evidence that TGFβ upregulates the expression of multiple receptor tyrosine kinases (RTKs), including IGF1R, EGFR, PDGFβR, and FGFR1 in human hepatocellular carcinoma (HCC) cells. This, in turn, sensitized HCC cells to individual cognate RTK ligands, leading to cell survival. Our data showed that the TGFβ-mediated increase in growth factor sensitivity led to evasion of apoptosis induced by the mutikinase inhibitor, sorafenib. Conversely, we observed that inhibition of the TGFβ signaling pathway by LY2157299, a TGFβRI kinase inhibitor, enhanced sorafenib-induced apoptosis, in vitro. Our findings disclose an important interplay between TGFβ and RTK signaling pathways, which is critical for hepatocellular cancer cell survival and resistance to therapy.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Akt; HCC; IGF1R; RTKs; TGFβ; sorafenib

Mesh:

Substances:

Year:  2016        PMID: 27862334      PMCID: PMC5712429          DOI: 10.1002/mc.22592

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  45 in total

Review 1.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.

Authors:  Tzu-Hsuan Lin; Yu-Yun Shao; Soa-Yu Chan; Chung-Yi Huang; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Clin Cancer Res       Date:  2015-05-14       Impact factor: 12.531

3.  Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.

Authors:  Kuen-Feng Chen; Hui-Ling Chen; Wei-Tien Tai; Wen-Chi Feng; Chih-Hung Hsu; Pei-Jer Chen; Ann-Lii Cheng
Journal:  J Pharmacol Exp Ther       Date:  2011-01-04       Impact factor: 4.030

4.  Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.

Authors:  A V Bakin; A K Tomlinson; N A Bhowmick; H L Moses; C L Arteaga
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

Review 5.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

6.  Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor.

Authors:  Jeffrey C Horowitz; Daniel Y Lee; Meghna Waghray; Venkateshwar G Keshamouni; Peedikayil E Thomas; Hengmin Zhang; Zongbin Cui; Victor J Thannickal
Journal:  J Biol Chem       Date:  2003-10-23       Impact factor: 5.157

7.  A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.

Authors:  Joan Fernando; Andrea Malfettone; Edgar B Cepeda; Roser Vilarrasa-Blasi; Esther Bertran; Giulia Raimondi; Àngels Fabra; Alberto Alvarez-Barrientos; Pedro Fernández-Salguero; Conrado M Fernández-Rodríguez; Gianluigi Giannelli; Patricia Sancho; Isabel Fabregat
Journal:  Int J Cancer       Date:  2014-08-04       Impact factor: 7.396

8.  Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Keith Stuart; Lawrence S Blaszkowsky; Alona Muzikansky; Donald P Reitberg; Jeffrey W Clark; Peter C Enzinger; Pankaj Bhargava; Jeffrey A Meyerhardt; Kerry Horgan; Charles S Fuchs; David P Ryan
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

9.  Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.

Authors:  Maria Serova; Annemilaï Tijeras-Raballand; Célia Dos Santos; Miguel Albuquerque; Valerie Paradis; Cindy Neuzillet; Karim A Benhadji; Eric Raymond; Sandrine Faivre; Armand de Gramont
Journal:  Oncotarget       Date:  2015-08-28

Review 10.  New Insights into the Crossroads between EMT and Stemness in the Context of Cancer.

Authors:  Isabel Fabregat; Andrea Malfettone; Jitka Soukupova
Journal:  J Clin Med       Date:  2016-03-12       Impact factor: 4.241

View more
  10 in total

1.  Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling.

Authors:  Sirichat Kaowinn; Seung Won Jun; Chang Seok Kim; Dong-Myeong Shin; Yoon-Hwae Hwang; Kyujung Kim; Bosung Shin; Chutima Kaewpiboon; Hyeon Hee Jeong; Sang Seok Koh; Oliver H Krämer; Randal N Johnston; Young-Hwa Chung
Journal:  Cell Oncol (Dordr)       Date:  2017-08-03       Impact factor: 6.730

Review 2.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

3.  TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR.

Authors:  Ella Bhagyaraj; Nancy Ahuja; Sumit Kumar; Drishti Tiwari; Shalini Gupta; Ravikanth Nanduri; Pawan Gupta
Journal:  Cell Cycle       Date:  2019-11-18       Impact factor: 4.534

Review 4.  Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.

Authors:  Xiang-Yuan Luo; Kong-Ming Wu; Xing-Xing He
Journal:  J Exp Clin Cancer Res       Date:  2021-05-18

5.  A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Authors:  R K Kelley; E Gane; E Assenat; J Siebler; P R Galle; P Merle; I O Hourmand; A Cleverly; Y Zhao; I Gueorguieva; M Lahn; S Faivre; K A Benhadji; G Giannelli
Journal:  Clin Transl Gastroenterol       Date:  2019-07       Impact factor: 4.488

Review 6.  Targeting TGFβ signal transduction for cancer therapy.

Authors:  Sijia Liu; Jiang Ren; Peter Ten Dijke
Journal:  Signal Transduct Target Ther       Date:  2021-01-08

Review 7.  The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications.

Authors:  Medine Zeynep Gungor; Merve Uysal; Serif Senturk
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

Review 8.  Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges.

Authors:  Monica A Kamal; Yasmine M Mandour; Mostafa K Abd El-Aziz; Ulrike Stein; Hend M El Tayebi
Journal:  Molecules       Date:  2022-08-28       Impact factor: 4.927

Review 9.  Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights.

Authors:  Xinchen Tian; Tinghao Yan; Fen Liu; Qingbin Liu; Jing Zhao; Huabao Xiong; Shulong Jiang
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

Review 10.  The role of long noncoding RNAs in hepatocellular carcinoma.

Authors:  Zhao Huang; Jian-Kang Zhou; Yong Peng; Weifeng He; Canhua Huang
Journal:  Mol Cancer       Date:  2020-04-15       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.